The second quarter promises big data reveals for Fibrogen, Travere, Argenx and Bavarian Nordic.
US Pdufa decisions loom for Apellis and Travere, while Menarini and Lilly got their approval firsts already.
Atacicept hits in phase 2, but uncompetitive data are seen as good news for its IgAN rivals.
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
The first half of 2022 was slow on the regulatory front, but plenty of big decisions remain for Bristol Myers Squibb, Apellis and others.